FDA Warns Compounders Against Using Dietary Supplement-Grade Glutathione for IV Injectables Following Adverse Events
Last updated 2026-09-01 · Source: fda.gov
Primary source: fda.gov: FDA Warns Compounders Against Using Dietary Supplement-Grade Glutathione for IV Injectables Following Adverse Events
The FDA has issued a warning to compounders, urging them to cease using dietary supplement-grade glutathione in products intended for intravenous injection. This alert comes in response to at least 30 reported adverse events linked to IV glutathione, emphasizing the critical importance of using appropriate ingredient grades for sterile compounded preparations. Compounders who received this ingredient from Medisca are specifically instructed to contact customers and discontinue its use.
What this means for your practice
This FDA warning carries significant implications for healthcare businesses that utilize or source compounded intravenous products, particularly those offering IV nutrient therapies, such as medspas and IV infusion clinics. Providers and practices must exercise heightened due diligence when obtaining compounded medications, ensuring that their compounding pharmacy partners adhere strictly to FDA guidelines regarding ingredient sourcing and quality. The use of dietary supplement-grade ingredients in injectable products poses substantial patient safety risks, as these ingredients may not meet the sterility, purity, or quality standards required for parenteral administration. Practices should review their procurement processes for all compounded injectables, verify their compounding pharmacy's accreditation and sourcing practices, and ensure that all products meet the necessary pharmaceutical standards to avoid potential adverse events, regulatory scrutiny, and liability.
Washington D.C. — On August 27, 2026, the U.S. Food and Drug Administration (FDA) released a critical safety warning directed at compounding pharmacies and other entities involved in preparing intravenous (IV) injectable products. The agency explicitly cautioned against the use of dietary supplement-grade glutathione as an ingredient in IV injectable formulations, citing a direct link to patient adverse events.
The Basis of the FDA's Warning
The FDA's announcement was prompted by a concerning discovery of at least 30 adverse events reported in connection with intravenous glutathione. This underscores a fundamental principle of pharmaceutical compounding: the quality and grade of starting materials are paramount, especially for sterile preparations administered directly into the bloodstream. Dietary supplement-grade ingredients, while potentially suitable for oral consumption, are not manufactured under the stringent controls required for injectable drug components and may lack the purity, potency, and sterility necessary for safe IV administration.
Specific Directives for Compounders
In its communication, the FDA provided clear instructions for compounders. They are urged to immediately cease the practice of incorporating dietary supplement-grade glutathione into any injectable products. Furthermore, the warning specifically named Medisca as a supplier, instructing compounders who have received this ingredient from Medisca to contact their customers without delay and discontinue the use of any such products.
Importance of Reporting Quality Problems
The agency also reiterated the importance of its MedWatch program, the FDA Safety Information and Adverse Event Reporting Program. Health professionals, patients, and consumers are encouraged to report any quality problems or adverse events related to FDA-regulated products through MedWatch. This reporting mechanism is crucial for the FDA to monitor product safety, identify emerging issues, and take timely regulatory action to protect public health.
MedWatch serves as the primary gateway for submitting reports concerning serious problems with human medical products, including prescription and over-the-counter medicines, biologics, medical devices, and combination products. By reporting, healthcare providers contribute vital data that informs FDA's safety alerts and regulatory decisions.
Regulatory Implications for Compounding Practices
This warning highlights the FDA's ongoing vigilance regarding the quality and safety of compounded medications. Compounding pharmacies, especially those operating as outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), are expected to adhere to current Good Manufacturing Practices (CGMP) for all products. The use of sub-standard ingredients represents a significant deviation from these requirements and can lead to serious patient harm.
For healthcare businesses, including telehealth providers, medspas, and IV infusion clinics, that rely on compounded products, this warning serves as a critical reminder to:
- Verify Sourcing: Ensure that all compounded injectable medications are sourced from reputable pharmacies that use only pharmaceutical-grade ingredients meeting official compendial standards (e.g., USP).
- Confirm Compliance: Confirm that compounding partners adhere to all relevant FDA regulations, including CGMP, and possess appropriate licenses and certifications.
- Educate Staff: Ensure all staff involved in procuring, preparing, or administering compounded medications are aware of the risks associated with non-pharmaceutical grade ingredients.
- Report Concerns: Promptly report any suspected quality issues or adverse reactions to the FDA via MedWatch, as well as to the compounding pharmacy.
The FDA's action underscores its commitment to ensuring the safety and quality of all drug products, including those prepared through compounding. Adherence to these guidelines is essential for patient safety and regulatory compliance.
Key Facts
| Detail | Value | |---|---| | Warning Date | August 27, 2026 | | Reason for Warning | At least 30 adverse events linked to intravenous glutathione | | Specific Instruction | Compounders must stop using dietary supplement-grade glutathione for IV injectables | | Affected Supplier Mentioned | Medisca (compounders who received ingredient from Medisca should contact customers and discontinue use) | | Reporting Mechanism | Report quality problems via MedWatch | | Affected Products | Intravenous glutathione injectable products |
Frequently Asked Questions
What is the FDA warning about?
The FDA is warning compounders to stop using dietary supplement-grade glutathione in products intended for intravenous (IV) injection.
Why did the FDA issue this warning?
The warning was issued due to at least 30 adverse events that have been linked to intravenous glutathione.
What should compounders do if they have dietary supplement-grade glutathione from Medisca?
Compounders who received this ingredient from Medisca should contact their customers and immediately discontinue its use.
How can I report a quality problem or adverse event related to this issue?
The FDA urges individuals to report any quality problems or adverse events through their MedWatch safety information and adverse event reporting program.
Does this warning apply to oral glutathione supplements?
The warning specifically addresses dietary supplement-grade glutathione *for IV injectables*, indicating concern about parenteral administration, not necessarily oral supplements.